Who owns PALISADE BIO, INC.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of PALI from SEC Form 13F filings across 124 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 124 institutions disclosed 173.4M shares of PALISADE BIO, INC. worth $362.4M — about 82% of shares outstanding; the largest disclosed holder is Soleus Capital Management, L.P.. Source: SEC Form 13F filings, parsed by EvidInvest.
124
13F holders
$362.4M
value, 2026 filers
82%
of shares outstanding (173.4M sh)
50
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of PALI's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Soleus Capital Management, L.P.NEW | 13.1M | $27.3M | 0.9% | 6.2% | new |
| 2 | B Group, Inc. | 11.4M | $23.9M | 11.2% | 5.4% | 0.0% |
| 3 | AMERIPRISE FINANCIAL INC | 11.1M | $23.2M | 0.0% | 5.2% | +27.2% |
| 4 | Jupiter Topco LLCNEW | 10.7M | $22.4M | 0.0% | 5.1% | new |
| 5 | BlackRock, Inc. | 10.4M | $21.8M | 0.0% | 4.9% | +456.2% |
| 6 | Octagon Capital Advisors LP | 10.3M | $21.5M | 1.9% | 4.9% | 0.0% |
| 7 | PERCEPTIVE ADVISORS LLC | 8.4M | $17.6M | 0.3% | 4% | -5.6% |
| 8 | RA CAPITAL MANAGEMENT, L.P. | 7.1M | $14.9M | 0.1% | 3.4% | 0.0% |
| 9 | FRANKLIN RESOURCES INC | 5.8M | $12.1M | 0.0% | 2.7% | 0.0% |
| 10 | Point72 Asset Management, L.P. | 5.3M | $11.0M | 0.0% | 2.5% | +1175.8% |
| 11 | Boxer Capital Management, LLC | 4.8M | $10.0M | 0.8% | 2.3% | 0.0% |
| 12 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.5M | $9.4M | 0.0% | 2.1% | 0.0% |
| 13 | Eversept Partners, LP | 4.2M | $8.7M | 0.5% | 2% | -16.1% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 3.8M | $7.9M | 0.0% | 1.8% | +143.2% |
| 15 | WELLINGTON MANAGEMENT GROUP LLP | 3.7M | $7.7M | 0.0% | 1.8% | +27.5% |
| 16 | GOLDMAN SACHS GROUP INC | 3.6M | $7.5M | 0.0% | 1.7% | -33.4% |
| 17 | FEDERATED HERMES, INC. | 3.1M | $6.6M | 0.0% | 1.5% | 0.0% |
| 18 | Squadron Capital Management LLC | 3.0M | $6.3M | 1.9% | 1.4% | 0.0% |
| 19 | Propel Bio Management, LLC | 2.6M | $5.4M | 2.8% | 1.2% | +131.6% |
| 20 | Vestal Point Capital, LP | 2.5M | $5.2M | 0.1% | 1.2% | 0.0% |
| 21 | STATE STREET CORP | 2.5M | $5.2M | 0.0% | 1.2% | +289.1% |
| 22 | MORGAN STANLEY | 2.5M | $5.2M | 0.0% | 1.2% | -45.6% |
| 23 | ORBIMED ADVISORS LLC | 2.3M | $4.9M | 0.1% | 1.1% | 0.0% |
| 24 | GREAT POINT PARTNERS LLC | 2.3M | $4.8M | 0.9% | 1.1% | -32.9% |
| 25 | SPHERA FUNDS MANAGEMENT LTD. | 2.3M | $4.7M | 0.6% | 1.1% | +30.2% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.